Intracarotid cisplatin chemotherapy for recurrent gliomas

M. S. Mahaley, S. W. Hipp, E. J. Dropcho, L. Bertsch, S. Cush, T. Tirey, G. Y. Gillespie

Research output: Contribution to journalArticle

66 Scopus citations


Forty patients with recurrent gliomas were treated with monthly intra-arterial infusions of cisplatin. Of the 35 evaluable patients, 12 (34%) responded with computerized tomography (CT) evidence of a decrease in tumor size; in 14 (40%) the tumor stabilized on CT scans, and in nine (26%) the disease progessed. The median survival period was 35.0 weeks for the responders and 27.5 weeks for all 35 patients. The primary toxicities were renal (reversible alterations in creatinine clearance), otological (severe hearing loss in one patient), and likely neurotoxicity in one patient who had received bilateral infusions following contralateral tumor progression. The authors are now using this form of regional chemotherapy sequentially before and following radiotherapy in newly diagnosed cases.

Original languageEnglish (US)
Pages (from-to)371-378
Number of pages8
JournalJournal of neurosurgery
Issue number3
StatePublished - Jan 1 1989
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Intracarotid cisplatin chemotherapy for recurrent gliomas'. Together they form a unique fingerprint.

  • Cite this

    Mahaley, M. S., Hipp, S. W., Dropcho, E. J., Bertsch, L., Cush, S., Tirey, T., & Gillespie, G. Y. (1989). Intracarotid cisplatin chemotherapy for recurrent gliomas. Journal of neurosurgery, 70(3), 371-378.